Bringing the fundamentals into focus…
Back to Lineage Cell Therapeutics, Inc.
How Lineage Cell Therapeutics, Inc. stacks up
LCTX · against 310 other Healthcare companies of similar size
Valuation
8/ 100
Near the bottom of its peers.
Ranked #199 of 311 · scores higher than 12% of peers
Bars: peers in each 10-point band of the valuation score113 peers with a valuation score of 0–9, including LCTX · Click a bar to see the companies
Why valuation scores 8?
Weighted metrics compared with all Healthcare companies.Mainly because of its earnings yield, EBITDA yield and free cash flow yield, which are weaker than most Healthcare peers.
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. Earnings yield: -12.6% vs peer median 1.5%
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. EBITDA yield: -12.7% vs peer median 4.0%
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. Free cash flow yield: -9.5% vs peer median 0.0%
Metric by metric
Position: dot = LCTX, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | LCTX | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 296 reported | -16.8% | -0.4% | 26% | 30% | |
| EBITDA yieldHigher is better · 317 reported | -12.7% | 1.9% | 22% | 50% | |
| Free cash flow yieldHigher is better · 164 reported | -9.5% | -9.5% | 50% | 20% | |
| Book yieldHigher is better · 300 reported | 23.9% | 54.8% | 23% | Context only |
Ranking by valuation score
Top 5 and the companies ranked around LCTX| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 1.1B HKD (≈$146M) | 99 | 72 | |
| 1 | 3.5B HKD (≈$451M) | 99 | 51 | |
| 1 | 1.4B HKD (≈$181M) | 99 | 61 | |
| 1 | 2.9B HKD (≈$365M) | 99 | 84 | |
| 1 | 3.1B HKD (≈$396M) | 99 | 61 | |
| 199 | 275M USD | 8 | 46 | |
| 199 | 327M USD | 8 | 11 | |
| 199 | 172M USD | 8 | 41 | |
| 199 | 319M USD | 8 | 28 | |
| 199 | 255M USD | 8 | 36 | |
| 199 | 264M USD | 8 | 30 | |
| 199 | 255M USD | 8 | 38 | |
| 199 | 264M USD | 8 | 24 | |
| 199 | 441M USD | 8 | 34 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score